Phase 3 N=200 Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
Osteoporosis
Primary: Number of Participants With Serum 25-hydroxyvitamin D >=50 ng/mL at Week 26 — 1; 3; 1; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,883 E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) — 55.0…
Phase 3 N=389 Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Meningococcal Meningitis
Primary: Percentages of Subjects With Human Complement Serum Bactericidal Activity (hSBA) Titers≥ 1:8, After One Dose of Either MenACWY-CRM Conjugate or Licensed Comparator…
Phase 3 N=357 Welchol as Monotherapy for Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Percent Change in Hemoglobin A1c — -0.41; -0.14 percentage change of hemoglobin A1c — p=0.0369
Phase 3 N=834 A Trial to Reduce Pneumonia in Nursing Home Residents
Pneumonia · Lower Respiratory Tract Infection
Primary: Pneumonia — 119; 94 participants
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Phase 3 N=682 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
Coronary Artery Disease · Coronary Heart Disease · Dyslipidemia
Primary: Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT) — -0.006; 0.000 mm/year — p=0.220
Phase 3 N=79 A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) — 91.7; 100.0; 38.5 Percentage of Participants
Phase 3 N=18 Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants
Gastroesophageal Reflux
Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day
Phase 3 N=340 A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
Pain
Primary: Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical…
Phase 3 N=299 Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial
Parkinson's Disease
Primary: The Change From Baseline in the UPDRS-III Score at 24 Months With Deep-brain Stimulation and Without Medication. — -12.9; -13.1 units on a scale
Phase 3 N=263 TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Lipodystrophy · HIV Infections
Primary: Changes From Baseline in Fasting Blood Glucose at Week 52 — 0; -2; 1 mg/dL — p=>0.05
Phase 3 N=4,363 Study of Quadrivalent Influenza Vaccine Among Children
Influenza
Primary: Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants…
Phase 3 N=66 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events
Phase 3 N=100 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland
Amphetamine Dependence
Primary: Number Negative Urines (Proportion Negative Urines) — 560; 634 Urine Drug Screen